Overview
Vahaticor has secured $23 million in a Series B funding round led by S3 Ventures, with participation from Intuitive Ventures and a strategic investor. The company is developing an a-flux reducer system to enhance myocardial perfusion for patients with coronary microvascular dysfunction, supporting early feasibility studies and engineering efforts.
Products
Loading...
Recent Deals
Investors: S3 Ventures, Intuitive Ventures
Vahaticor has secured $23 million in a Series B funding round led by S3 Ventures, with participation from Intuitive Ventures and a strategic investor. The company is developing an a-flux reducer system to enhance myocardial perfusion for patients with coronary microvascular dysfunction, supporting early feasibility studies and engineering efforts.